About this Research Topic
Familial cancer is defined through diagnosis of the same or related cancers in two or more family members. Familial cancer is an important part of cancer genetics, as it can help us better understand cancer etiology. Family history of cancer offers a cheap tool for cancer prevention because healthy family members can be offered guidance about avoiding environmental risk factors and screening options for early detection of tumors. However, in China, research of familial cancer faces many difficulties. At first, though there are numerous clinicians in China, only a few of them are well versed in the diagnosis, treatment and family management of familial cancer. Additionally, obtaining a reliable family history may not be straightforward because, in many local cultures, cancers, particularly advanced cancers, are not openly discussed between family members. Even in medical settings, information to the patients or their family members may be limited.
This Research Topic aims to collect and present the latest data of Chinese familial cancer, including incidence, screening strategies, clinical practice, and family management. We aim to expand the knowledge and understanding of familial cancer in China. In studies reporting familial risks, it is important that the authors consider the reliability of the family histories reported.
We welcome Original Research and Reviews that explore, but are not limited to, the following list of themes:
- Investigation of novel pathogenic genes of hereditary tumors with necessary functional experiments.
- Epidemiological family studies of sufficient size on one or more cancer types.
- Screening of familial cancer: Insights into the screening strategies of familial cancer in the context of Chinese birth control.
- Clinical practice of familial cancer: How clinical genetic counseling recommends gene testing and transmission of the results to patients and/or relatives? How the costs are distributed? The numbers of patients should be provided.
- Advances in assisted reproductive technology, such as preimplantation genetic diagnosis (PGD) in familial cancer. The volume of patients should be present.
- Mutation analysis of novel pathogenic genes/cancer predisposing genes of familial cancer, as long as family histories are considered in patient stratification and contributing to risk assessment.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
This Research Topic aims to collect and present the latest data of Chinese familial cancer, including incidence, screening strategies, clinical practice, and family management. We aim to expand the knowledge and understanding of familial cancer in China. In studies reporting familial risks, it is important that the authors consider the reliability of the family histories reported.
We welcome Original Research and Reviews that explore, but are not limited to, the following list of themes:
- Investigation of novel pathogenic genes of hereditary tumors with necessary functional experiments.
- Epidemiological family studies of sufficient size on one or more cancer types.
- Screening of familial cancer: Insights into the screening strategies of familial cancer in the context of Chinese birth control.
- Clinical practice of familial cancer: How clinical genetic counseling recommends gene testing and transmission of the results to patients and/or relatives? How the costs are distributed? The numbers of patients should be provided.
- Advances in assisted reproductive technology, such as preimplantation genetic diagnosis (PGD) in familial cancer. The volume of patients should be present.
- Mutation analysis of novel pathogenic genes/cancer predisposing genes of familial cancer, as long as family histories are considered in patient stratification and contributing to risk assessment.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Keywords: Familial Cancer, Genetic Epidemiology, Genetic Counseling, Screening and Mutation Analysis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
